Cardiol Therapeutics: First patient enrolls in Phase 2 Study of CardiolRx Pericarditis
Vancouver, BC –News Direct– Cardiol Therapeutics
David Elsley, CEO at Cardiol Therapeutics shared information about a milestone the company reached. He said that the first patient was enrolled into a Phase II open label pilot study of CardiolRx in patients suffering from recurrent pericarditis. Proactive spoke with Elsley about the study, which is meant to measure improvement in objective measures of the disease and determine if it is possible to wean patients from background treatment including corticosteroids while they take CardiolRx. It is anticipated that the study will enroll 25 patents.
Canada’s Proactive Initiative Financial News
Contact Details
Canada’s Proactive Initiative
Proactive Canada
+1 604-688-8158
Newsdirect.com: View the source version https://newsdirect.com/news/cardiol-therapeutics-says-first-patient-enrolled-in-phase-2-study-of-cardiolrx-for-pericarditis-132503438